WT1 TCR-transduced T cells: Phase I/II started

Cell Therapy Catapult began an open-label, U.K. Phase I/II trial to evaluate 2 dose levels of WT1 TCR-transduced T cells in up to 18 patients. This year, the company plans to begin a trial in myelodys...